Bortezomib in newly diagnosed multiple myeloma

被引：6
|
作者：
Berenson, James R. [1 ]
机构：
[1] Inst Myeloma & Bone Canc Res, W Hollywood, CA 90069 USA
来源：
NATURE REVIEWS CLINICAL ONCOLOGY | 2009年 / 6卷 / 05期
关键词：
RANDOMIZED PHASE-III; COMBINATION THERAPY; PREDNISONE; MELPHALAN; TIME;
D O I：
10.1038/nrclinonc.2009.47
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Preclinical studies have shown that new agents such as bortezomib not only demonstrate anti-multiple-myeloma activity as single agents but also enhance the efficacy of both chemotherapy and steroids. a randomized trial has established that bortezomib not only improves response rates but also prolongs the lives of patients with multiple myeloma who are not candidates for high-dose chemotherapy.
引用
收藏
页码：255 / 256
页数：2
相关论文
共 50 条
  • [31] Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with newly diagnosed/untreated multiple myeloma
    Poenisch, Wolfram
    Holzvogt, Bruno
    Ploetze, Madlen
    Andrea, Marc
    Bourgeois, Malvina
    Heyn, Simone
    Zehrfeld, Thomas
    Hammerschmidt, Doreen
    Schwarz, Maik
    Edelmann, Thomas
    Becker, Cornelia
    Hoffmann, Franz Albert
    Schwarzer, Andreas
    Kreibich, Ute
    Gutsche, Kerstin
    Reifenrath, Kolja
    Winkelmann, Cornelia
    Krahl, Rainer
    Remane, Yvonne
    Hennig, Evelin
    Schliwa, Thomas
    Lindner, Tom
    Kaiser, Thorsten
    Vucinic, Vladan
    Behre, Gerhard
    Niederwieser, Dietger
    [J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2014, 140 (11) : 1947 - 1956
  • [32] Bendamustine and Prednisone in combination with Bortezomib (BPV) in the treatment of patients with newly diagnosed/untreated multiple myeloma
    Poenisch, W.
    Holzvogt, B.
    Ploetze, M.
    Andrea, M.
    Bourgeois, M.
    Heyn, S.
    Zehrfeld, T.
    Hammerschmidt, D.
    Schwarz, M.
    Edelmann, T.
    Becker, C.
    Hoffmann, F-A
    Schwarzer, A.
    Kreibich, U.
    Gutsche, K.
    Reifenrath, K.
    Winkelmann, C.
    Krahl, R.
    Remane, Y.
    Hennig, E.
    Lindner, T.
    Kaiser, T.
    Vucinic, V.
    Behre, G.
    Niederwieser, D.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 152 - 152
  • [33] General Aspects and Mechanisms of Peripheral Neuropathy Associated With Bortezomib in Patients With Newly Diagnosed Multiple Myeloma
    Broyl, Annemiek
    Jongen, Joost L. M.
    Sonneveld, Pieter
    [J]. SEMINARS IN HEMATOLOGY, 2012, 49 (03) : 249 - 257
  • [34] Efficacy and safety of bortezomib maintenance in patients with newly diagnosed multiple myeloma: a meta-analysis
    Sun, Chun-yan
    Li, Jun-ying
    Chu, Zhang-bo
    Zhang, Lu
    Chen, Lei
    Hu, Yu
    [J]. BIOSCIENCE REPORTS, 2017, 37
  • [35] SAFETY AND EFFICACY OF SUBCUTANEOUS VERSUS INTRAVENOUS BORTEZOMIB IN PATIENTS WITH NEWLY ELDERLY DIAGNOSED MULTIPLE MYELOMA
    Bacchiarri, F.
    Nozzoli, C.
    Antonioli, E.
    Staderini, M.
    Barone, F.
    Guarrera, A.
    Messeri, M.
    Coltro, G.
    Grieco, P.
    Bosi, A.
    [J]. HAEMATOLOGICA, 2017, 102 : 167 - 167
  • [36] Response to bortezomib in newly diagnosed multiple myeloma- a single centre experience from India
    Rajan, V.
    N, G.
    Nair, S. G.
    [J]. ANNALS OF ONCOLOGY, 2015, 26 : 90 - 90
  • [37] Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with newly diagnosed/untreated multiple myeloma
    Wolfram Pönisch
    Bruno Holzvogt
    Madlen Plötze
    Marc Andrea
    Malvina Bourgeois
    Simone Heyn
    Thomas Zehrfeld
    Doreen Hammerschmidt
    Maik Schwarz
    Thomas Edelmann
    Cornelia Becker
    Franz Albert Hoffmann
    Andreas Schwarzer
    Ute Kreibich
    Kerstin Gutsche
    Kolja Reifenrath
    Cornelia Winkelmann
    Rainer Krahl
    Yvonne Remane
    Evelin Hennig
    Thomas Schliwa
    Tom Lindner
    Thorsten Kaiser
    Vladan Vucinic
    Gerhard Behre
    Dietger Niederwieser
    [J]. Journal of Cancer Research and Clinical Oncology, 2014, 140 : 1947 - 1956
  • [38] Treatment of newly diagnosed myeloma: Bortezomib-based triplet
    Rajan, Archana M.
    Rajkumar, S. Vincent
    [J]. SEMINARS IN ONCOLOGY, 2016, 43 (06) : 700 - 702
  • [39] Reduced weekly subcutaneous doses of bortezomib in combination with cyclophosphamide and dexamethasone for newly diagnosed multiple myeloma
    Ashrafi, Farzaneh
    Moghaddas, Azadeh
    Darakhshandeh, Ali
    [J]. JOURNAL OF RESEARCH IN PHARMACY PRACTICE, 2020, 9 (01) : 56 - 59
  • [40] BENDAMUSTINE AND PREDNISONE IN COMBINATION WITH BORTEZOMIB (BPV) IN THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED/UNTREATED MULTIPLE MYELOMA
    Poenisch, W.
    Holzvogt, B.
    Ploetze, M.
    Andrea, M.
    Lange, T.
    Niederwieser, D.
    [J]. HAEMATOLOGICA, 2014, 99 : 362 - 363
12345